Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)

NCT03885089 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03885089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03885089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
October 21, 2019
Completion date
March 8, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erythrodermic psoriasis, psoriasis arthropathica, psoriasis vulgaris, pustular psoriasis